Anpac Biomedical Technology Co., Ltd. (“Anpac Bio”), a company engaged in early detection of cancer, recently announced that it had received the first payment from a Malaysian customer at the end of February 2023. Biotech has previously signed an equipment purchase contract for the purchase of cancer detection equipment from Anpac Biotech, with a total amount of approximately 10 million yuan (US$1.5 million). The cancer detection equipment is developed and manufactured based on the company’s new multi-cancer detection patented technology – “Cancer Differentiation Analysis Technology” (hereinafter referred to as “CDA”). As the first important sales of Anpac’s cancer detection equipment in Southeast Asia, it is another milestone for Anpac. It marks that Anpac has officially entered the global cancer detection equipment market, and also confirms that Anpac has officially entered the global cancer detection equipment market. Biotech’s new technologies, reputation and ability to penetrate vast global markets. In addition to Malaysia, Anpac Biotech is also in business negotiations with relevant companies and institutions in many other countries.

According to the terms of the purchase contract, Anpac Biotech will provide cancer detection equipment as well as maintenance services, consumables and equipment parts to Malaysian customers. After the equipment is sold, the company will continue to generate ongoing revenue from the sale of services, consumables and equipment parts. The Malaysian client plans to establish a biomedical laboratory, obtain Laboratory Developed Test (LDT) certification, and perform cancer testing for a fee.

Anpac Bio’s CDA technology is based on measuring biophysical properties in blood. Compared with traditional technologies, it has several major advantages, including the ability to detect a variety of cancers at an early stage, while having low cost, good bioinformation security, relatively simple operation, and high sensitivity and specificity. According to a 2021 report by Frost & Sullivan, an authoritative U.S. market analysis and research company, Anpac Biotech ranks globally in terms of commercial sample size and total sample size for next-generation multi-(pan-) cancer early screening. First. At the same time, Anpac Biotech is continuing to conduct one of the world’s earliest and multi-year follow-up studies on multiple cancers with a large sample size (as of February 2023, more than 18,000 people have been enrolled in this follow-up study).

Dr. Yu Chang, co-founder of Anpac Biotech, said: “Outside of China and the United States, our innovative cancer detection technology has also begun to be recognized in other parts of Asia. Because our technology has many unique advantages (multi-cancer detection, low-cost cost, with good bioinformatics security, early detection capabilities, and high sensitivity and specificity) and consistency with local needs (these areas have huge market size and demand for cancer screening and risk assessment in the general population), we CDA technology is expected to have great revenue and development growth potential in the region. We are very satisfied with achieving this important milestone achievement, which shows that Anpac Biotech has entered the global equipment sales stage, which means that more and more experts and customers are accepting this new and great innovative detection method. With the continuous upgrading of people’s health needs, biophysical-based detection technology and its advantages are gradually being recognized and accepted by more and more customers and experts, and Gradually becoming a new force to promote the development of the industry. We will also work harder to uphold the beautiful vision of ‘keeping humans away from cancer’, adhere to the original intention of starting earlier and going further, and continue to develop innovative theories of multi-cancer screening and cancer treatment. Success in early screening.”

Anpac Biomedical Technology Co., Ltd. (hereinafter referred to as “Anpac Bio”) is a biotechnology company listed on Nasdaq that engages in early detection of cancer. Anpac Biotech has two qualified medical laboratories in China. A 2021 market research report by Frost & Sullivan, an authoritative U.S. market research company, shows that Anpac Biotech ranks first in both commercial sample size and total sample size for early screening of multiple (pan) cancers. No. 1 in the world (cumulative as of January 2021). A large number of clinical trials and years of cancer risk assessment follow-up results show that Anpac Biotech’s Cancer Differentiation Analysis (CDA) technology and platform can detect the risk of more than 20 types of cancer with high sensitivity and specificity.

< Online paper release screenshot >

The Clinical Research Center of Shanghai Jiao Tong University School of Medicine (“Clinical Research Center of Shanghai Jiao Tong University School of Medicine”) is a leading domestic clinical research center integrating scientific research, services, management and discipline construction. Guided by clinical needs and problems, the Clinical Research Center of Jiaotong University School of Medicine collaboratively builds a sustainable clinical research collaboration network that aggregates the clinical resource advantages of 12 affiliated hospitals to provide strong support for improving disease prevention and treatment and protecting public health.

<CDA technical analysis Diagram >

On March 31, 2023, the two units jointly announced the latest positive results of their joint first, multi-year, multi-cancer detection follow-up study.

Previously, Anpac Biotech has conducted single-blind and double-blind retrospective studies with large sample sizes with multiple hospitals. For example, at the 2019 ASCO annual meeting, Anpac Biotech and a number of hospitals jointly published a paper titled “A novel biophysical based marker with multilevel, multi-parameter expression for early stage cancer detection”. The paper shows that Anpac’s CDA technology achieved high sensitivity and specificity of 85.2% and 93% respectively in detecting stage I non-small cell lung cancer.

Anpac Biotechnology also published a paper “Cancer differentiation analysis technology as a novel technology for cerebral cancer screening” at the 2019 ASCO annual meeting. The results shown in the paper show that Anpac’s CDA technology detects brain cancer through blood, with a sensitivity and specificity of 92.3% and 96.6%.

This time includes the technical paper “A New Cancer Screening Method Based on Biophysics – Progress and Evaluation of Cancer Differentiation Analysis Technology” written by Anpac Biotech in conjunction with the Clinical Research Center of Jiaotong University School of Medicine and many other well-known medical institutions. It was well-known in the UK The journal “Expert Review of Molecular Diagnostics” accepted and published (impact factor 5.233).

The study is divided into two phases. The first phase, the Routine Health Checkup Study (RHCS), included a total of 75,942 adult healthy individuals from all over the country recruited between January 2015 and December 2020; the second phase, The Prospective Population Cohort Study (PPCS) included healthy individuals over 40 years old recruited from different communities in Changning District, Shanghai, from January to December 2019, a total of 1,957 people.

The paper reported that as of December 2020, 7,999 of the 75,942 healthy people in the first phase had obtained effective follow-up information. The information showed that 48 people were found to have cancer (including colorectal cancer, lung cancer) at or after receiving CDA testing. , prostate cancer, breast cancer, gastric cancer, pancreatic cancer, liver cancer, etc.), the specificity of CDA detection in this study was as high as 95.8%, and the accuracy was as high as 95.6%; among the 1,957 healthy people in the second phase, 10 were initially diagnosed with cancer ( Including lung cancer, breast cancer, colorectal cancer, etc.), the specificity of CDA detection in the study was as high as 93.7%.

The research in this paper shows that the CDA test can distinguish blood samples from healthy individuals and cancer patients. Two independent studies in the paper both confirmed that CDA is highly specific (>93%) in the detection of the general population, which has obvious implications for the detection of the general population. The advantages of CDA cancer differentiation analysis technology by measuring and analyzing a variety of biophysical properties to distinguish blood samples from healthy individuals and cancer patients have been applied and the socio-economic value has been generated.

From July 15 to 17, 2022, the ZAODX World Early Cancer Screening Conference, focusing on the research and development and transformation and application of global early screening cutting-edge technologies, was successfully held in Guangzhou. The conference focused on the three major perspectives of “world pattern”, “China exploration” and “solutions” , conduct in-depth discussions around the three major aspects of “technological power”, “productivity” and “market power”, build a top global communication platform, and help industries improve their global cooperation capabilities and market transformation and application capabilities of scientific and technological achievements.

Dr. Yu Chang, founder of Anpac Biotechnology, was invited to participate in a roundtable discussion at the “Multi-omics and Multi-Cancer Liquid Biopsy Frontier Forum” on July 15, and together with industry experts and scholars focused on “Multi-omics and Multi-Cancer” “Opportunities and Challenges of Liquid Biopsy” will be discussed as the core to jointly promote the development of the early cancer screening industry. At the same time as attending the meeting, Dr. Yu Chang also won the title of “Ingenuity Figure” of this year’s Golden Screen Award.

At the same time, Anpac Biotechnology, Dean Diagnostics, Exact Sciences and other companies were ranked jointly on the list of leading companies (listed) in the “Golden Screening Award” selection activity launched by Zaosifing.com, and were awarded the title of “Golden Screening Award·Leading Company” . Anpac Biotechnology has been deeply involved in the field of early cancer screening for more than 10 years with its profound scientific research strength. It has proposed innovative methodologies of “multiple (pan) cancers” and “multi-level, multi-parameter screening” and adopted innovative biophysical technologies for cancer applications. The practice of detection, and independently developed CDA technology with many advantages including multi-cancer, high cost-effectiveness, early detection, high sensitivity and high specificity, provide important ideas, innovative concepts and scientific and technological strength for the development of early cancer screening. This award is a high degree of recognition and praise for the achievements of Anpac Biotech.

As one of the first companies to propose innovative methodology and cancer detection concepts of “multi-cancer” and “multi-level, multi-parameter screening”, Anpac Biotech independently develops “cancer risk” based on the correlation between biophysical properties and cancer risk. Assessment (CDA)” technology to make risk assessments of the presence and likelihood of cancer. After years of research and development and practice, we have made progress in many aspects in the field of early cancer screening, and this innovative technology has benefited the public, saved human lives, successfully achieved localization, and occupied the commanding heights of technology.

Looking back on the innovation path of more than ten years, Anpac Biotech has never stopped working hard and has always advocated the innovative concept of multi-cancer screening: including reports on clinical trial results since the beginning of 2010 (including multiple ASCO paper publications), several Ten patent applications, disclosures and press releases covering multiple cancer screening claims in multiple countries. As of March 31, 2022, Anpac Biotechnology has applied for 260 patents in 20 countries and regions around the world, of which 155 have been authorized.

In terms of scientific research, Anpac Biotechnology has also been forging ahead. In November 2021, the team published an academic paper “A Review of New Cancer Screening Methods” in the well-known British journal “EXPERT REVIEW OF MOLECULAR DIAGNOSTICS” with a team from Shanghai Jiao Tong University School of Medicine and many other well-known medical institutions, with an impact factor of 5.223. In April 2022, Clinical trials and results of CDA technology used in lung cancer efficacy evaluation were announced at the AACR Annual Meeting of the American Association for Cancer Research.

In recent years, with the active promotion and collaboration of more and more peer companies, the innovative theory of multi-cancer screening has gradually been widely accepted by the industry. But what cannot be ignored is that Anpac Biotech from China started earlier and has gone further!

Frost & Sullivan (“Sullivan”), a well-known market analysis and research company, in a recent research report (based on data accumulation as of the end of January 2021) ranked Anpac Biotech as a global pan-(multiple) The No. 1 company in cancer screening and detection, including next-generation cancer screening and detection technologies, including circulating cancer cells (CTCs), circulating tumor DNA (ct-DNA), exosomes, cancer risk assessment (CDA), and mRNA and other emerging technologies. At present, the CDA technology platform jointly developed by Anpac Biotech and medical institutions can detect the risk of more than 20 types of cancer with its high sensitivity and specificity. As of March 31, 2022, Anpac Biotech has a large database in the global next-generation cancer early screening field, and has successfully completed the verification of more than 250,000 cases, and is still growing.

Healthy China, early screening first. In the past ten years, Anpac Biotechnology has been a concept leader in multi-cancer detection and a pioneer and advocate of innovative methodologies, making contributions to the concept, technology development and practice in this field. made significant contributions. In the future, Anpac Biotechnology will not forget its original intention, continue to uphold the beautiful vision of “keeping humans away from cancer”, delve into multi-cancer screening innovation, early cancer screening and treatment, and promote the rapid development of early cancer screening!

About Anpac Biotechnology

Anpac Biotechnology is a biotechnology company focused on early cancer screening and detection. As of March 31, 2022, it owned 155 patents. Anpac Biotech has two certified clinical laboratories in China and one CLIA and CAP accredited clinical laboratory in the United States. A range of cancer screening and detection tests are available, including CDA (Cancer Risk Assessment Technology), biochemical, immunological and genomic testing. A market research report by Frost & Sullivan shows that Anpac Biotech ranks first in the world in terms of sample volume for multi-cancer screening and testing (cumulative as of January 2021). These clinical experiments show that Anpac Bio’s CDA technology and platform can detect the risk of more than 20 types of cancer with high sensitivity and specificity.

Abstract: The academic paper “Clinical Experiments and Results of the Application of Innovative Biophysics-based CDA Technology in Efficacy Evaluation of Lung Cancer” written by Anpac Biotech in collaboration with the School of Life Sciences of Fudan University and Shanghai Changhai Hospital was approved by the American Association for Cancer Research. (AACR) accepted, and will be presented and published as a poster at the 113th American Association for Cancer Research (AACR) Annual Meeting on April 12, 2022. This paper announced the latest important results of clinical verification of the Cancer Differentiation Analysis Technology (CDA) developed by Anpac Bio-Innovation for the evaluation of efficacy in lung cancer. Based on the correlation statistics and analysis of CDA detection data collected during treatment of 686 lung cancer patients and the clinical response (efficacy) of these lung cancer patients to lung cancer treatment, it was initially verified that CDA data and clinical response have a statistically good correlation. Sex, CDA technology is expected to become an effective and innovative method for efficacy evaluation in cancer treatment.

Recently, Anpac Biotechnology jointly presented and published a paper “Based on Innovative Biophysics” in the form of a poster at the 113th American Association for Cancer Research (AACR) Annual Meeting held from April 8 to 13, 2022. “Clinical Experiments and Results of CDA Technology Applied to Lung Cancer Therapeutic Response” (A Novel Bio-Physical Based CDA Approach to Lung Cancer Therapeutic Response). The co-authors of the paper are the National Key Laboratory team from the School of Life Sciences of Fudan University, a well-known Chinese university, and the excellent medical team from Shanghai Changhai Hospital.

The 113th American AACR Conference – Anpac Biotech

Lung cancer has the highest mortality and morbidity among malignant tumors in the world, and its prognosis and survival rate are significantly lower than other tumors. The research paper published this time announced the clinical experiments and results of the application of Anpac Biotech’s innovative CDA technology in the evaluation of the efficacy of lung cancer. It involved a total of 686 patients diagnosed with different types of lung cancer, and CDA detection of peripheral blood was taken. We have conducted clinical studies and evaluated the efficacy after treatment and found that:

1) The overall results show that the lower the CDA value, the better the efficacy (the higher the CDA value, the worse the efficacy);

2) The CDA value of the complete response (CR) ① group is significantly lower than the other 3 groups (partial response (PR) ②) stable disease (SD) ③, and progressive disease (PD) ④), and there is a statistically significant difference ( P value is lower than 0.05. In most cases, P value is much lower than 0.05);

3) The CDA value of adenocarcinoma lung cancer (ADC) in the complete response (CR) group is significantly lower than that in the stable disease (SD) group;

4) For non-metastatic lung cancer, the CDA value in the complete response (CR) group was significantly lower than that in the stable disease (SD) group.

The results showed that the CDA value in the complete response (CR) patient group was the lowest, and the CDA value in the early lung cancer group was consistent with the efficacy. CDA technology is expected to be one of the effective evaluation methods in the treatment of lung cancer (especially early-stage lung cancer).

The 113th American AACR Conference – Anpac Biological Paper Poster

Dr. Yu Chang, co-founder of Anpac Bio, said: “We are very pleased that Anpac Bio published the latest and important paper on the application of CDA technology in the efficacy evaluation of lung cancer at the AACR meeting. The results of this paper once again verified the CDA technology The clinical significance and the possibility that its application can be extended to the field of cancer efficacy evaluation. Once again demonstrates the feasibility and clinical value of our innovative biophysical approach in many aspects of cancer, and provides the possibility for CDA technology to be used in clinical cancer efficacy evaluation. and clinical value. We will continue to invest in research and development, accelerate the verification and transformation of our innovative results through industry-university-research cooperation, and continue to make positive contributions to the human fight against cancer.”

About AACR
The American Association for Cancer Research (AACR) was founded in 1907. It is the oldest and largest scientific organization dedicated to cancer research in the world. It currently has more than 48,000 members in 127 countries, including laboratories, Translational and clinical researchers; other health care professionals and cancer advocates; members include the AACR Academy’s 256 fellows; 54 Nobel Prize winners. The mission of AACR is to prevent and treat pain through research, education, communication, and collaboration. AACR’s scientific breadth and reputation for excellence attract researchers in the field, promote the exchange of new knowledge and ideas among scientists in the field of cancer research, provide training opportunities for the next generation of researchers, and increase public awareness of cancer.

About Anpac Biotechnology
Anpac Biotech is a biotechnology company focused on early cancer screening and detection as well as cancer treatment. As of September 30, 2021, it owned 150 patents. Anpac Biotech has two certified clinical laboratories in China and one CLIA and CAP accredited clinical laboratory in the United States. A range of cancer screening and detection tests are available, including CDA (Cancer Risk Assessment Technology), biochemical, immunological and genomic testing. A market research report by Frost & Sullivan shows that Anpac Biotech ranks first in the world in terms of sample volume for multi-cancer screening and testing (cumulative as of January 2021). These clinical experiments show that Anpac Bio’s CDA technology and platform can detect the risk of more than 20 types of cancer with high sensitivity and specificity.

Efficacy evaluation classification

① Complete response (CR, complete response): all target lesions disappear, no new lesions appear, and tumor markers are normal, lasting at least 4 weeks.

② Partial response (PR, partial response): The sum of the maximum diameters of target lesions is reduced by ≥30% and maintained for at least 4 weeks.

③ Stable disease (SD): The sum of the maximum diameters of target lesions shrinks to less than PR, or increases to less than PD.

④ Progressive disease (PD): the sum of the maximum diameters of target lesions increases by at least ≥20%, or new lesions appear.

Shangguan News Report:
All cancer categories have relatively high specificity, above 95%, indicating that this blood testing technology is suitable for cancer screening in the general population.

Recently, the Clinical Research Center of Shanghai Jiao Tong University School of Medicine and Anpac Biotech, together with experts from the Children’s Hospital of Fudan University, Shanghai Tongren Hospital and other units, published an article introducing a new type of cancer in the international medical journal “Molecular Diagnostics Expert Review” The paper on screening methods provides a theoretical basis for the application of cancer risk assessment (CDA) technology in large-scale cancer screening, allowing multiple cancers to be detected early with low-cost blood tests, allowing patients to receive early treatment.

Publish papers online

Due to high costs and immature methods, routine health examinations currently often lack effective cancer screening tests. In response to this pain point, CDA technology has developed rapidly in recent years because scientific researchers have discovered that the biophysical properties of blood and related components are related to the occurrence of cancer, and can be detected through micromechanics, acoustics, optics, electricity, magnetism, etc. Identification using a variety of detectable biophysical properties.

In this cutting-edge field, Dr. Yu Chang, co-founder of Anpac Biotechnology, led the team to propose innovative methodologies and cancer detection concepts of “pan-cancer” and “multi-level, multi-parameter screening”, and independently developed a series of CDA technologies. They collect clinically significant weak signals at the protein level, cellular level and molecular level, and then conduct risk assessments on the existence and possibility of cancer through multi-parameter calculation model analysis. They are early, forward-looking, cost-effective, Appropriate sensitivity, relatively high specificity and other characteristics.

A paper published in Molecular Diagnostics Expert Review shows that researchers conducted a two-stage study to evaluate the value of CDA technology. The first phase of the cross-sectional study included 75,942 healthy individuals during routine health examinations; the second phase was a population-based prospective cohort study including 1,957 healthy community members. In a cross-sectional study and a prospective population-based cohort study, they found 48 and 10 cases of cancer, respectively. Since this study is a healthy population screening and prospective study, its specificity and sensitivity will be further improved as follow-up continues and more patients are diagnosed in medical institutions. Based on follow-up data as of June 30, 2020, researchers found that the CDA technology test can differentiate between healthy and cancer groups. Among the 75,942 healthy individuals in the first phase, based on 7,999 people who were successfully followed up, at the 95% confidence level, the specificity of CDA technology was greater than 95%, and the sensitivity was 66.7% for gastric cancer, 66.70% for liver cancer, and 62.50% for lung cancer. Overall, in both studies, the specificity was greater than 93% and the sensitivity was greater than 55%.

Application of CDA technology in follow-up (N=7999)

Among the 1,957 prospective cohort study participants in the second phase, 10 were diagnosed with cancer for the first time. Research shows that men in the 70-85 age group have higher CDA values, while women are less affected by age. The distribution in each age group is roughly the same, and the CDA value in 75-80 years old is slightly higher. Taking a CDA value greater than 48 as the critical point, the sensitivity and specificity of gastric cancer, liver cancer and lung cancer are relatively close.
Overall, all cancer categories have relatively high specificity, above 95%, indicating that this blood testing technology is suitable for cancer screening in the general population. At present, the CDA technology platform jointly developed by Anpac Biotech and medical institutions can detect the risk of more than 20 types of cancer with its high sensitivity and specificity.

Report source: Shangguan News